Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Tyrphostin AG30 (AG30) is a potent and selective inhibitor of EGFR tyrosine kinase. Tyrphostin AG30 (AG30) selectively prevents c-ErbB from inducing self-renewal in primary erythroblasts and prevents c-ErbB from activating STAT5.
Targets |
EGFR
|
---|---|
References |
|
Molecular Formula |
C10H7NO4
|
---|---|
Molecular Weight |
205.17
|
Exact Mass |
205.0375
|
Elemental Analysis |
C, 53.40; H, 4.03; Cl, 7.88; F, 8.45; N, 15.57; O, 10.67
|
CAS # |
122520-79-0
|
Related CAS # |
122520-79-0
|
Appearance |
Solid powder
|
SMILES |
C1=CC(=C(C=C1/C=C(\C#N)/C(=O)O)O)O
|
InChi Key |
CJMWBHLWSMKFSM-XVNBXDOJSA-N
|
InChi Code |
InChI=1S/C10H7NO4/c11-5-7(10(14)15)3-6-1-2-8(12)9(13)4-6/h1-4,12-13H,(H,14,15)/b7-3+
|
Chemical Name |
(E)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enoic acid
|
Synonyms |
Tyrphostin AG30; AG 30; AG-30; AG30
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: ~41 mg/mL (199.8 mM)
Ethanol: ~3 mg/mL (14.6 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (10.14 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (10.14 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 4.8740 mL | 24.3700 mL | 48.7401 mL | |
5 mM | 0.9748 mL | 4.8740 mL | 9.7480 mL | |
10 mM | 0.4874 mL | 2.4370 mL | 4.8740 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Effect of EGFR antagonist AG30 on EGF-induced WISP-2/CCN5 mRNA expression in MCF-7 cells. Mol Cancer Res . 2005 Mar;3(3):151-62. td> |